Polycystic Ovary Syndrome Clinical Trial
Official title:
Vitamin D Supplementation Prior to in Vitro Fertilization in Women With Polycystic Ovary Syndrome: a Protocol of a Multicenter Randomised Double-blind Placebo-controlled Clinical Trial
NCT number | NCT04082650 |
Other study ID # | VDPI |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 15, 2020 |
Est. completion date | March 10, 2024 |
This multicenter double-blinded placebo-controlled randomised trial aims to evaluate the effectiveness of vitamin D supplementation prior to IVF on the live birth rate in women with PCOS. Women with PCOS scheduled for IVF will be enrolled. Eligible participants will be randomised 1:1 to receive oral capsules of 4000IU vitamin D per day or placebo for around 12 weeks until the day of triggering.
Status | Recruiting |
Enrollment | 860 |
Est. completion date | March 10, 2024 |
Est. primary completion date | February 2, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 42 Years |
Eligibility | Inclusion criteria 1. Women aged 20 to 42 years old; 2. Diagnosed with PCOS (Rotterdam Criteria); 3. Scheduled for IVF; 4. Written informed consent. Exclusion criteria 1. Women who had three or more failed IVF cycles; 2. Women scheduled for preimplantation genetic testing; 3. Known Vitamin D allergy; 4. Women with a history of chronic absorption syndrome or bile dysplasia, or parathyroid dysfunction, or kidney stones, or blood Calcium ion concentration greater than 2.6mmol/L (normal value 2.25 - 2.75mmol/L (9 to 11mg/dl), or hyperphosphataemia (1.61mmol/L), or metabolic-related bone disease, or chronic diseases that may cause bone abnormalities (liver and kidney insufficiency); 5. Women receiving treatments for tuberculosis, convulsions, and epilepsy because medications treating these diseases may affect the metabolism of vitamin D. 6. Women undergoing an IVF treatment with donor oocytes. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hospital | Beijing | Beijing |
China | Women's Hospital, Zhejiang University School of Medicine | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Women's Hospital School Of Medicine Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with live birth | The primary outcome is live birth after the first embryo transfer. Live birth is defined as the delivery of at least one baby after 24 weeks of gestation that exhibits any sign of life. | 1 day after delivery | |
Secondary | Number of Participants with Cumulative live birth | Cumulative live birth: defined as live birth resulting from pregnancies that occur within 6 months after randomization. | 6 months after randomization of the last participant | |
Secondary | Number of Participants with Clinical pregnancy | Clinical pregnancy: defined as at least one gestational sac on ultrasound at around 7 weeks' gestation with the detection of heart beat activity after the completion of the first embryo transfer; | 4 weeks after embryo transfer | |
Secondary | birth weight | Weight of newborns at delivery. | The day of delivery | |
Secondary | Number of Participants with miscarriage | miscarriage was defined as a positive pregnancy test but no detectable heart rate before 24 weeks' gestation after the completion of the first transfer; | 24 gestational weeks in maximum | |
Secondary | Number of Participants with Ongoing pregnancy | defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond after the completion of the first transfer | at 12 weeks' gestation | |
Secondary | Number of Participants with Biochemical pregnancy | defined with a positive pregnancy test | 2 weeks after embryo transfer | |
Secondary | Number of Participants with Ectopic pregnancy | defined as embryo implanted at any site other than the endometrial lining of the uterus cavity after the completion of the first transfer | 4 weeks after embryo transfer | |
Secondary | Number of Participants with Ovarian hyperstimulation syndrome | defined according to the Golan criteria. Moderate OHSS is diagnosed by the presence of ascites on ultrasonography in addition to abdominal distension and discomfort with or without nausea, vomiting and/or diarrhea. Severe OHSS is diagnosed when there is clinical evidence of ascites and/or hydrothorax or breathing difficulties with or without hemoconcentration, coagulation abnormalities and diminished renal function. | From the day of oocyte retrieval to two weeks after embryo transfer | |
Secondary | Number of available embryos for transfer | non | 5 days after oocyte retrieval | |
Secondary | Number of Participants with Pre-eclampsia | defined as the development of gestational hypertension with proteinuria (=300 mg/24-hour urine collection or 30 mg/dL in single urine sample) of new onset after 20 weeks of gestation after the completion of the first transfer | 20 weeks of gestation till delivery | |
Secondary | Number of Participants with Gestational hypertension | defined as the development of blood pressure greater than 140/90 mmHg after pregnancy without proteinuria or other signs of preeclampsia after the completion of the first transfer; | 20 weeks of gestation till delivery | |
Secondary | Number of Participants with Premature rupture of membrane | PROM was defined as rupture of the amniotic membranes before the onset of labor including PROM at term and preterm PROM. | The day of delivery | |
Secondary | Number of Participants with Postpartum hemorrhage | defined as the loss of 500 ml of blood or more after completion of the third stage of labor after the completion of the first transfer | 1 day after delivery | |
Secondary | Number of Participants with Preterm delivery | Defined as delivery of a fetus at less than 37 and more than 28 weeks' gestational age after the completion of the first transfer | 1 day after delivery | |
Secondary | Number of Participants with Gestational diabetes mellitus | defined as carbohydrate intolerance of variable severity with onset or first recognition during pregnancy as determined from the diagnosis in the obstetrical medical record | Up to ten months once the participants get pregnancy | |
Secondary | Number of Participants with Placenta previa | defined as a placenta that is implanted over or very close to the internal cervical orifice | after 24 weeks of gestation | |
Secondary | Number of Participants with Stillbirth | defined as the absence of signs of life at or after birth after the completion of the first transfer | 1 day after delivery | |
Secondary | Apgar score | non | 1 minute or 5 minutes after delivery | |
Secondary | Serum Vitamin D binding protein, glucose, insulin, Calcium ion concentration | non | The day of oocyte retrieval | |
Secondary | Serum vitamin levels | Serum vitamin levels at the triggering day | One day before oocyte retrieval |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT06158932 -
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04932070 -
Berberine and Polycystic Ovary Syndrome
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03480022 -
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
|
Phase 3 | |
Active, not recruiting |
NCT03043924 -
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT05246306 -
Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
|
||
Completed |
NCT05981742 -
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
|
Phase 2 | |
Completed |
NCT05702957 -
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05029492 -
Effect of Visceral Manipulation on PCOS
|
N/A | |
Completed |
NCT02924025 -
Motivational Interviewing as an Intervention for PCOS
|
N/A | |
Not yet recruiting |
NCT02255578 -
Endobarrier Treatment in Women With PCOS
|
Phase 3 | |
Not yet recruiting |
NCT00883259 -
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
|
Phase 4 | |
Withdrawn |
NCT01638988 -
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
|
Phase 3 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Completed |
NCT01462864 -
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
|
N/A | |
Recruiting |
NCT01431352 -
Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT00989781 -
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
|
N/A |